Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 7/20 | 0.50 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.47 |
| ▸ | QDPR | P09417 | 3/20 | 0.47 |
| ▸ | KHK | P50053 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20395786 | 1.00 | HTR2C (0.50) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL12373870 | 0.99 | HTR2C (0.49) | HTR2CQDPRSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL2275244 | 0.87 | HTR2C (0.40) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL12374234 | 0.85 | HTR2C (0.39) | HTR2CQDPRSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL18113566 | 0.85 | ALOX5AP (0.44) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL20414655 | 0.85 | ALOX5AP (0.44) | HTR2CQDPRSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL18113568 | 0.84 | HTR2C (0.44) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL20420134 | 0.82 | HTR2C (0.43) | HTR2CQDPRSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL2276107 | 0.82 | HTR2C (0.47) | HTR2CQDPRSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL2273883 | 0.82 | HTR2C (0.50) | HTR2CQDPRSIGMAR1KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115058-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2021-04-22 | — | — | US | disclosed |
| WO-2021067266-A1 | PYRROLIDINYL-BASED COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2021-04-08 | — | — | WO | disclosed |
| US-10934304-B2 | Spirocyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| CN-107849053-B | Spiro compounds | 里科瑞尔姆IP控股有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20200207776-A1 | SPIROCYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2020-07-02 | — | — | US | disclosed |
| EP-3277690-B1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| EP-3277690-A1 | SPIROCYCLIC COMPOUNDS | Kalyra Pharmaceuticals, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016161160-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| EP-2260031-B1 | COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115058-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885SIGMAR1 2013/4885QDPR 2060/4885 |
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885SIGMAR1 2013/4885QDPR 2060/4885 |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885SIGMAR1 2013/4885QDPR 2060/4885 |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | HTR2C 3854/4885SIGMAR1 1297/4885QDPR 598/4885 |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885SIGMAR1 2013/4885QDPR 2060/4885 |
| US-20200207776-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885SIGMAR1 2013/4885QDPR 2060/4885 |
| US-10934304-B2 | Spirocyclic compounds | PKD1, AR, PKD2 | HTR2C 2823/4885SIGMAR1 2013/4885QDPR 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.